Gilead Sciences (MEX:GILD) Ending Cash Position : MXN162,152 Mil (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Gilead Sciences Ending Cash Position?

Gilead Sciences's Ending Cash Position for the quarter that ended in Mar. 2025 was MXN162,152 Mil.

Gilead Sciences's quarterly Ending Cash Position increased from Sep. 2024 (MXN99,180 Mil) to Dec. 2024 (MXN208,369 Mil) but then declined from Dec. 2024 (MXN208,369 Mil) to Mar. 2025 (MXN162,152 Mil).

Gilead Sciences's annual Ending Cash Position declined from Dec. 2022 (MXN105,512 Mil) to Dec. 2023 (MXN103,288 Mil) but then increased from Dec. 2023 (MXN103,288 Mil) to Dec. 2024 (MXN208,369 Mil).

Gilead Sciences Ending Cash Position Historical Data

The historical data trend for Gilead Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Ending Cash Position Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

119,292.32

109,503.73

105,512.35

103,288.30

208,369.30

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															78,301.13	50,783.33	99,180.04	208,369.30	162,151.69

Gilead Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Gilead Sciences's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	126906.935	+	81462.364
	=	208,369

Gilead Sciences's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	204397.876	+	-42246.183
	=	162,152

Gilead Sciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MEX:GILD) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Peru 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).